-
FREE BIO-TECH STOCK CATALYST REPORT FOR WEEK OF 05-31-2026 TO 06-06-2026
I’m excited to announce the release of my latest free bio tech stock catalyst report for the upcoming week. This new free stock report highlights bio tech companies that have an upcoming important event to help traders and investors make informed decisions in today’s dynamic environment. Each stock symbol is a link to a stock…
$BYSI, $CGEM, $CING, $CRDF, $CUE, $EQ, $VOR, 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, 2026 Jefferies Global Healthcare Conference, biopharmaceutical, clinical-research, EULAR 2026 Congress (European Congress of Rheumatology), fda, new drug application, pr-newswire, press-releases, Webcast -
Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs
NYSEAMERICAN: $ATNM Source: Read More
-
FREE BIO-TECH STOCK CATALYST REPORT FOR WEEK OF 05-24-2026 TO 05-30-2026
I’m excited to announce the release of my latest free bio tech stock catalyst report for the upcoming week. This new free stock report highlights bio tech companies that have an upcoming important event to help traders and investors make informed decisions in today’s dynamic environment. Each stock symbol is a link to a stock…
-
FREE BIO-TECH STOCK CATALYST REPORT FOR WEEK OF 05-17-2026 TO 05-23-2026
I’m excited to announce the release of my latest free bio tech stock catalyst report for the upcoming week. This new free stock report highlights bio tech companies that have an upcoming important event to help traders and investors make informed decisions in today’s dynamic environment. Each stock symbol is a link to a stock…
$CGON, $CRBP, $FATE, $NBP, $NMRA, $TNXP, $VTGN, $ZNTL, A.G.P.’s Annual Virtual Healthcare Conference, biopharmaceutical, clinical-research, fda, H.C. Wainwright 4th Annual BioConnect Investor Conference, ISPOR 2026, new drug application, pr-newswire, press-releases, RBC Capital Markets Global Healthcare Conference, Stifel 2026 Virtual Oncology Forum -
Compass Therapeutics (CMPX) enters the second half of 2026 in a strong financial position
NASDAQ: $CMPX Compass Therapeutics enters the second half of 2026 in a strong financial position, though its stock has recently experienced significant volatility following the long-awaited data readout for its lead program. Cash Runway As of the most recent financial updates in early 2026, Compass Therapeutics is exceptionally well-capitalized for a clinical-stage biotech: 2026 Pipeline…
-
FREE BIO-TECH STOCK CATALYST REPORT FOR WEEK OF 05-03-2026 TO 05-09-2026
I’m excited to announce the release of my latest free bio tech stock catalyst report for the upcoming week. This new free stock report highlights bio tech companies that have an upcoming important event to help traders and investors make informed decisions in today’s dynamic environment. Each stock symbol is a link to a stock…
-
Beyond the Growth Chart: New Long-Term Data on VOXZOGO® for Achondroplasia
NASDAQ: $BMRN The landscape of pediatric endocrinology is shifting. At the Pediatric Endocrine Society’s (PES) 2026 Annual Meeting in San Francisco, new data presented by BioMarin Pharmaceutical Inc. has provided a clearer picture of how long-term treatment with VOXZOGO® (vosoritide) impacts children with achondroplasia. While height is often the most visible metric in skeletal dysplasias,…
-
New Two-Year Data on CRENESSITY® (crinecerfont) Shows Lasting Health Benefits for Children with Classic Congenital Adrenal Hyperplasia
NASDAQ: $NBIX Recent findings presented at the Pediatric Endocrine Society 2026 Annual Meeting offer a promising outlook for the pediatric community living with classic congenital adrenal hyperplasia (CAH). Neurocrine Biosciences has released new two-year data from the Phase 3 CAHtalyst® Pediatric study, revealing that long-term treatment with CRENESSITY® (crinecerfont) provides durable hormone control and allows…
-
Viatris Advances Contraceptive Care: New Data on Weekly Low-Dose Patch to be Presented at ACOG 2026
NASDAQ: $VTRS As we approach the 2026 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting in Washington, D.C., the medical community is turning its attention toward significant advancements in reproductive health. Viatris Inc. recently announced it will present six new abstracts regarding its investigational low-dose estrogen combined hormonal contraceptive (CHC) weekly…
-
Kodiak Sciences Advances Pipeline and Unveils New Clinical Data for KSI-101 in Uveitis Treatment
NASDAQ: $KOD Kodiak Sciences Inc. has announced significant progress in its clinical and scientific programs, with plans to present new data at the 2026 American Uveitis Society (AUS) Meeting and the Association for Research in Vision and Ophthalmology (ARVO) Meeting. These updates center on the clinical performance of KSI-101 in treating macular edema secondary to…
-
Expanding Global Protection: Genprex Secures Key Patent for Reqorsa® Gene Therapy in Israel
NASDAQ: $GNPX In a significant move to strengthen its international intellectual property portfolio, clinical-stage gene therapy company Genprex, Inc. (NASDAQ: GNPX) recently announced that the Israel Patent Office (ILPO) has officially granted a patent covering the use of its proprietary Reqorsa® gene therapy (quaratusugene ozeplasmid) in combination with PD-1 antibodies for cancer treatment. Strategic Intellectual…
-
Insmed Sets Sights on May 2026: What Investors Should Watch
NASDAQ: $INSM Insmed Incorporated has officially announced its participation in a series of upcoming investor conferences throughout May 2026. This move signals a proactive effort by the biopharmaceutical company to maintain transparency and provide clarity regarding its ongoing clinical pipeline and commercial strategies. Why These Appearances Matter Investor conferences serve as a critical bridge between…
-
Advancing Crohn’s Disease Treatment: The Potential of RedHill’s RHB-204
NASDAQ: $RDHL The landscape of Crohn’s disease (CD) treatment may be on the cusp of a significant shift. RedHill Biopharma Ltd. recently announced promising in vitro testing results for RHB-204, a next-generation oral formulation that represents a targeted therapeutic approach to the condition. By focusing on Mycobacterium avium subspecies paratuberculosis (MAP), RedHill is pursuing a strategy…
-
Advancing Large-Bore Venous Access: New Study Validates VASCADE MVP® XL Performance
NYSE: $HAE In the rapidly evolving field of cardiac electrophysiology, the precision of venous access closure is as critical as the primary procedure itself. Haemonetics Corporation recently announced compelling new clinical evidence regarding its VASCADE MVP® XL venous vascular closure system, marking a significant milestone for procedural safety and efficiency in large-bore venous access. The…
-
New Two-Year Data Supports Long-Term Management of Classic Congenital Adrenal Hyperplasia with CRENESSITY®
NASDAQ: $NBIX For individuals living with classic congenital adrenal hyperplasia (CAH), the standard of care has long presented a difficult dilemma. While patients require glucocorticoids (GCs) to survive, the historical reliance on supraphysiologic doses—doses higher than what the body naturally produces—has carried a heavy burden of long-term health risks, including metabolic complications, bone density loss,…
-
Advancing Oncology: Mount Sinai Health System Partners with SOPHiA GENETICS to Elevate Precision Cancer Care
NASDAQ: $SOPH In a significant move for the future of precision medicine, the Mount Sinai Health System has announced a strategic collaboration with SOPHiA GENETICS. This partnership marks a new chapter for one of the nation’s most prestigious academic health systems, as it integrates the AI-powered SOPHiA DDM™ Platform to refine its genomic testing capabilities…
-
Hoth Therapeutics Leverages OpenClaw™ AI Platform to Advance Drug Discovery
NASDAQ: $HOTH Hoth Therapeutics Deploys OpenClaw™ AI Platform to Accelerate Drug Discovery Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, has announced a significant strategic advancement with the deployment of OpenClaw™, its new, advanced AI-enabled computational platform. This move signifies a major commitment to integrating artificial intelligence into the core of its drug discovery and development…
-
Alliance for Genomic Discovery Scales Up: Regeneron Joins, Multiomic Data Initiative Launched
NASDAQ: $ILMN Genomic Research Reaches New Heights with Expansion and Proteomic Integration The landscape of genomic discovery is undergoing a significant transformation with major developments announced by the Alliance for Genomic Discovery (AGD), a collaboration spearheaded by Illumina, Inc. and Nashville Biosciences, LLC (NashBio). Two key announcements signal a massive leap forward: the addition of…